Department of Infectious Diseases, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,Iran.
Curr Drug Saf. 2022;17(3):269-273. doi: 10.2174/1574886316666211005102711.
Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, the side effects on skin of the medications used for COVID-19, such as famotidine, have not been studied.
This case series aims to present challenges in defining cutaneous manifestations of famotidine in the context of COVID-19.
We identified patients from Imam Khomeini hospital complex who were admitted to the ward due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), were taking famotidine and having cutaneous rash. Clinical data were obtained through observation and intervention.
We found 4 SARS-CoV-2 patients with cutaneous manifestations. The mean (±SD) age of the patients was 57±2 years, 3 patients were men, and their COVID-19 symptoms appeared 10±3 days before admission. The most common symptoms were cough and shortness of breath. All the patients were admitted for hypoxemic respiratory failure. Patients received famotidine for gastrointestinal prophylaxis, and all 4 patients developed Acral macular mountainous skin lesions in the upper and lower extremities, then we discontinued famotidine and lesions were recovered completely in all patients.
These cases prompted us to inform clinicians about cutaneous complications of famotidine in COVID-19 patients.
在 COVID-19 感染患者中观察到了各种皮肤表现。然而，尚未研究 COVID-19 所用药物（如法莫替丁）对皮肤的副作用。
本病例系列旨在阐述在 COVID-19 背景下定义法莫替丁皮肤表现的挑战。
我们从伊玛目霍梅尼医院综合大楼中确定了因严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）住院并接受法莫替丁治疗且出现皮疹的患者。通过观察和干预获取临床数据。
我们发现了 4 例具有皮肤表现的 SARS-CoV-2 患者。患者的平均（±SD）年龄为 57±2 岁，3 例为男性，其 COVID-19 症状在入院前 10±3 天出现。最常见的症状是咳嗽和呼吸急促。所有患者均因低氧性呼吸衰竭而入院。患者接受法莫替丁进行胃肠道预防，所有 4 例患者的上下肢均出现肢端斑片状山形皮肤病变，随后我们停止用法莫替丁，所有患者的病变均完全恢复。
这些病例促使我们告知临床医生 COVID-19 患者中法莫替丁的皮肤并发症。
